Back

Wearable neuroprosthesis improves mobility and reduces pain in neuropathic participants

Gozzi, N.; Chee, L.; Odermatt, I.; Kikkert, S.; Preatoni, G.; Valle, G.; Pfender, N.; Beuschlein, F.; Wenderoth, N.; Zipser, C. M.; Raspopovic, S.

2024-05-09 endocrinology
10.1101/2024.05.08.24306164
Show abstract

Peripheral neuropathy (PN) is the most common complication of diabetes. It is characterized by sensory loss which often causes major health consequences including foot ulceration, chronic pain, poor mobility and increased risk of falls. However, present treatments do not counteract the cause of the disease, namely lack of sensory feedback, but rather aim at partial and temporal symptoms relief (e.g. analgesics for pain or creams for ulcers healing). Electrical stimulation is a promising solution for sensory restoration, but it is yet unknown if it can elicit perceivable sensations in PN damaged nerves and whether it could lead to any health or functional benefits. To this aim, we designed a wearable sensory neuroprosthesis providing targeted neurostimulation at the ankle level (NeuroStep) restoring feet lost sensations. We tested it in 14 participants with PN, evaluating its effects on functional outcomes and pain, and the cortical activation related to the restored sensations. Our system was able to restore lost sensations in all participants. The nerves of PN participants resulted significantly less excitable and sensitive than healthy individuals (N=22). Thanks to the neurostimulation, participants improved cadence and functional gait, with even stronger improvements in individuals with higher risk of falls. A full day of NeuroStep use led to a clinically significant reduction of 30.4% {+/-} 9.2% in neuropathic pain. Restored sensations activated cortical patterns, as measured via fMRI, similar to the naturally located foot sensations, thus not requiring training by the user. NeuroStep restores intuitive sensations in PN participants, improving mobility and decreasing pain, possibly replacing multiple inefficient treatments. It holds potential to drastically improve patients quality of life thanks to functional and health benefits, while paving the way to new effective neuromodulation treatments.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Scientific Reports
based on 701 papers
Top 6%
13.7%
2
Frontiers in Physiology
based on 18 papers
Top 0.1%
11.6%
3
PLOS ONE
based on 1737 papers
Top 66%
5.5%
4
npj Digital Medicine
based on 85 papers
Top 4%
5.5%
5
European Journal of Neuroscience
based on 10 papers
Top 0.1%
5.5%
6
Journal of Neural Engineering
based on 19 papers
Top 0.5%
4.7%
7
Nature Communications
based on 483 papers
Top 20%
3.1%
8
eLife
based on 262 papers
Top 7%
3.1%
50% of probability mass above
9
Sensors
based on 18 papers
Top 0.8%
2.9%
10
BMJ Open Diabetes Research & Care
based on 14 papers
Top 0.9%
2.9%
11
Human Brain Mapping
based on 53 papers
Top 3%
2.5%
12
Frontiers in Endocrinology
based on 20 papers
Top 2%
2.4%
13
Frontiers in Neuroscience
based on 29 papers
Top 1%
2.3%
14
Informatics in Medicine Unlocked
based on 11 papers
Top 0.9%
1.9%
15
Schizophrenia
based on 13 papers
Top 0.7%
1.6%
16
JMIR Public Health and Surveillance
based on 45 papers
Top 8%
1.2%
17
SLEEP
based on 11 papers
Top 0.7%
1.2%
18
Diabetes, Obesity and Metabolism
based on 14 papers
Top 2%
0.8%
19
IEEE Journal of Biomedical and Health Informatics
based on 14 papers
Top 3%
0.8%
20
JMIRx Med
based on 29 papers
Top 5%
0.8%
21
The Journal of Clinical Endocrinology & Metabolism
based on 26 papers
Top 3%
0.8%
22
Advanced Science
based on 12 papers
Top 2%
0.8%
23
Pilot and Feasibility Studies
based on 12 papers
Top 2%
0.7%
24
Scientific Data
based on 30 papers
Top 4%
0.7%
25
Journal of Clinical Medicine
based on 77 papers
Top 17%
0.7%
26
PeerJ
based on 46 papers
Top 12%
0.7%
27
Brain Communications
based on 79 papers
Top 7%
0.7%
28
Neurology
based on 38 papers
Top 7%
0.7%
29
Journal of NeuroEngineering and Rehabilitation
based on 14 papers
Top 3%
0.7%
30
Biology
based on 11 papers
Top 2%
0.7%